Table 1

Patient demographics

No of patients
Male:female14:8
Median age (range)64 (45–84)
Type of cancer
 Melanoma15 (68%)
 Renal4 (18%)
 Urothelial2 (9%)
 NSCLC1 (4%)
Charlson Comorbidity Index median8 (range: 6–10)
Immunotherapy
 Anti-CTLA-4 and anti-PD-18 (36%)
 Anti-PD-1 only10 (45%)
 Anti PD-1 and anti-LAG-31 (4%)
 Anti-CTLA-4/anti-PD-1 monotherapy or combination1 (4%)
No of immunotherapy cycles prior to diarrhea or colitis
 1–25 (23%)
 3–511 (50%)
 6–104 (18%)
 >102 (9%)
Gastrointestinal symptoms
 Diarrhea22 (100%)
 Nocturnal defecation7 (32%)
 Urgency5 (23%)
 Abdominal pain/cramps6 (27%)
 Bleeding3 (14%)
Other IrAEs
 Respiratory3
 Endocrine6
 Hepatological2
 Dermatological8
 Hematological1
 Rheumatological1
 Gastroenterological2
 Neurological1
 No IrAEs6
Treatments for CPI colitis prior to BD
 Systemic corticosteroids22 (100%)
 Intravenous corticosteroids11 (50%)
 Anti-TNF (infliximab/adalimumab)13 (59%)
 Vedolizumab3 (14%)
Adverse events on systemic corticosteroids
 Any adverse event6 (27%)
 Poor glycemic control2 (9%)
 Weight gain1 (4%)
 Infection3 (14%)
Median no of days of continuous CS prior to BD (IQR)58 (27–170)
Median no of days between last biological dose and BD initiation (range)8 (1–190)
  • BD, beclomethasone dipropionate; CPI, checkpoint inhibitor.